GrifoisGRFS
About: As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
Employees: 23,737
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
162% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 13
138% more call options, than puts
Call options by funds: $11M | Put options by funds: $4.64M
67% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 5 (+2) [Q3]
67% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 36
32% more capital invested
Capital invested by funds: $930M [Q2] → $1.22B (+$293M) [Q3]
17% more funds holding
Funds holding: 127 [Q2] → 148 (+21) [Q3]
3.81% less ownership
Funds ownership: 56.48% [Q2] → 52.67% (-3.81%) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for GRFS.
Financial journalist opinion
Based on 8 articles about GRFS published over the past 30 days